Opium Addiction Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | DemeRx IB, Inc./atai Life Sciences, MediciNova, BioXcel Therapeutics, USWM, LLC

Posted on
by

Opium Addiction Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | DemeRx IB, Inc./atai Life Sciences, MediciNova, BioXcel Therapeutics, USWM, LLC
The Key Opium Addiction Companies in the market include – DemeRx IB, Inc./atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., USWM, LLC (dba US WorldMeds, Thomas Jefferson University, and others.

 

DelveInsight’s “Opium Addiction Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Opium Addiction, historical and forecasted epidemiology as well as the Opium Addiction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Opium Addiction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Opium Addiction Market Forecast

 

Some of the key facts of the Opium Addiction Market Report:

  • The Opium Addiction market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In February 2025, Glucagon-like peptide receptor agonists (GLP-1RAs), such as Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s tirzepatide (Mounjaro, Zepbound), have gained significant attention for their blockbuster sales in diabetes and obesity treatment. As interest in these drugs grows, researchers are expanding their potential applications beyond metabolic disorders, with ongoing trials exploring their effects on cardiovascular, neurodegenerative, and respiratory diseases. Now, these medications are being studied for an unexpected new indication: opioid use disorder (OUD).

  • In September 2024, Spark Biomedical, a pioneer in wearable neurostimulation technology, collaborated with renowned research and behavioral health organizations, Battelle Memorial Institute and Hazelden Betty Ford Foundation, to transform opioid use disorder (OUD) recovery treatments. Their partnership will focus on creating an artificial intelligence (AI) algorithm aimed at detecting and managing opioid withdrawal symptoms and cravings.

  • In February 2024, Proniras, a clinical-stage biotechnology firm, concluded a successful Series B funding round totaling $4.65 million. This financing will facilitate the Phase I clinical trial of PRN-001-01 (tezampanel), a novel treatment for opiate withdrawal. Tezampanel, the company’s flagship program, is engineered to modulate glutaminergic signaling, focusing on aiding recovery from opioid addiction. Its mechanism targets the reduction of excessive brain activity within circuits linked to drug withdrawal, addiction, and mental health disorders, all while avoiding direct interaction with the opioid system.

  • DelveInsight’s analysis indicates that in 2022, there were approximately 9,264,786 cases of opioid misuse in the US. It is projected that these numbers will decrease significantly at a compound annual growth rate (CAGR) over the forecast period from 2023 to 2032.

  • In 2022, within EU4 countries and the UK, the UK reported the highest number of cases of long-term opioid usage at 339,351, while Spain recorded the lowest with 61,871 cases. It is anticipated that these cases will decrease across EU4 and the UK.

  • The number of cases of Opioid Withdrawal Symptoms in Japan was reported to be 160,278 in 2022, with projections indicating a decrease to 135,570 cases by 2032.

  • DelveInsight forecasts that the number of cases of opioid misuse in EU4 and the UK will decline from 1,422,332 cases in 2022 to approximately 1,051,533 cases by 2034. The projected decrease is expected to occur at a compound annual growth rate (CAGR) of -2.1% during the forecast period from 2023 to 2032.

  • Key Opium Addiction Companies: DemeRx IB, Inc./atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., USWM, LLC (dba US WorldMeds, Thomas Jefferson University, and others

  • Key Opium Addiction Therapies: DMX-1002 (Ibogaine HCl), MN-166, BXCL501, Standard of Care with Lofexidine, Buprenorphine Injection, Dexmedetomidine, and others

  • The Opium Addiction market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Opium Addiction pipeline products will significantly revolutionize the Opium Addiction market dynamics.

 

Opium Addiction Overview

Opium Addiction is a chronic disorder characterized by the compulsive use of opium and its derivatives, leading to physical and psychological dependence. Opium, derived from the poppy plant, contains alkaloids like morphine and codeine, which have potent analgesic effects but also high addiction potential.

Long-term use can result in tolerance, withdrawal symptoms, and a strong craving for the drug. Opium addiction can severely impact health, causing respiratory issues, cognitive impairment, and social dysfunction. Treatment options include medication-assisted therapy (such as methadone or buprenorphine), counseling, and rehabilitation programs to help individuals overcome dependency.

 

Get a Free sample for the Opium Addiction Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/opium-addiction-market

 

Opium Addiction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Opium Addiction Epidemiology Segmentation:

The Opium Addiction market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Opium Addiction

  • Prevalent Cases of Opium Addiction by severity

  • Gender-specific Prevalence of Opium Addiction

  • Diagnosed Cases of Episodic and Chronic Opium Addiction

 

Download the report to understand which factors are driving Opium Addiction epidemiology trends @ Opium Addiction Epidemiology Forecast

 

Opium Addiction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Opium Addiction market or expected to get launched during the study period. The analysis covers Opium Addiction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Opium Addiction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Opium Addiction Therapies and Key Companies

  • DMX-1002 (Ibogaine HCl): DemeRx IB, Inc./atai Life Sciences

  • MN-166: MediciNova

  • BXCL501: BioXcel Therapeutics Inc.

  • Standard of Care with Lofexidine: USWM, LLC (dba US WorldMeds

  • Buprenorphine Injection: Thomas Jefferson University

  • Dexmedetomidine: BioXcel Therapeutics Inc

 

Discover more about therapies set to grab major Opium Addiction market share @ Opium Addiction Treatment Landscape

 

Opium Addiction Market Strengths

  • Globally, there is a growing recognition of the opioid crisis, which has raised awareness about Opium Addiction and the need for effective treatments.

  • Pharmaceutical companies are investing in research and development aimed at creating more effective and safer treatments for opioid withdrawal, including medications and behavioral therapies.

  • Government initiatives and regulations prioritize opioid withdrawal management, fostering market growth.

 

Opium Addiction Market Opportunities

  • The shift towards precision medicine offers possibilities for developing targeted treatments, allowing for more effective and personalized interventions in OWS management.

  • The high prevalence of opioid addiction creates a significant market demand for withdrawal syndrome treatments, providing opportunities for companies operating in this space.

  • The current and emerging market is dominated by buprenorphine-based products, hence introduction of a therapy with a novel mechanism can lead to significant market growth.

 

Scope of the Opium Addiction Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Opium Addiction Companies: DemeRx IB, Inc./atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., USWM, LLC (dba US WorldMeds, Thomas Jefferson University, and others

  • Key Opium Addiction Therapies: DMX-1002 (Ibogaine HCl), MN-166, BXCL501, Standard of Care with Lofexidine, Buprenorphine Injection, Dexmedetomidine, and others

  • Opium Addiction Therapeutic Assessment: Opium Addiction current marketed and Opium Addiction emerging therapies

  • Opium Addiction Market Dynamics: Opium Addiction market drivers and Opium Addiction market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Opium Addiction Unmet Needs, KOL’s views, Analyst’s views, Opium Addiction Market Access and Reimbursement

 

To know more about Opium Addiction companies working in the treatment market, visit @ Opium Addiction Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Opium Addiction Market Report Introduction

2. Executive Summary for Opium Addiction

3. SWOT analysis of Opium Addiction

4. Opium Addiction Patient Share (%) Overview at a Glance

5. Opium Addiction Market Overview at a Glance

6. Opium Addiction Disease Background and Overview

7. Opium Addiction Epidemiology and Patient Population

8. Country-Specific Patient Population of Opium Addiction

9. Opium Addiction Current Treatment and Medical Practices

10. Opium Addiction Unmet Needs

11. Opium Addiction Emerging Therapies

12. Opium Addiction Market Outlook

13. Country-Wise Opium Addiction Market Analysis (2019–2032)

14. Opium Addiction Market Access and Reimbursement of Therapies

15. Opium Addiction Market Drivers

16. Opium Addiction Market Barriers

17. Opium Addiction Appendix

18. Opium Addiction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/